ClinicalTrials.gg
Active, not recruitingNCT05393180Updated Nov 6, 2026

CONVERGE Post-Approval Study (PAS)

An interventional study of Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF in Chronic Atrial Fibrillation, sponsored by AtriCure, Inc.. Active, not recruiting at 13 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by AtriCure, Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Atrial Fibrillation by AtriCure, Inc. — 2 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · AtriCure, Inc..

Enrollment
12th of 23
53 · median 53
Started
2022
with 1 other
No phase
16 of 27
1 open now
Registered
24th of 27
by date

Among the 27 studies in Atrial Fibrillation by AtriCure, Inc., this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2022, is one of 16 with no phase, and was the 24th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 27 studies in Atrial Fibrillation by AtriCure, Inc. are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Atrial Fibrillation by AtriCure, Inc., or all of them as a file.
02

Study summary

The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.

Read the detailed description

In accordance with FDA's Guidance on Balancing Premarket and Post Market Data Collection for Devices Subject to Premarket Approval AtriCure proposes to conduct a post-approval study following the Agency's PMA approval of the CONVERGE pivotal trial.

Currently there are no FDA-approved treatment options available for patients diagnosed with drug refractory, long-standing persistent AF, which is known to increase the risk of stroke by five-fold.

The CONVERGE trial was conducted to address the treatment need in patients with advanced forms of AF, using a hybrid epicardial plus endocardial ablation approach. The Hybrid Convergent procedure and the EPi-Sense device have evolved over the past decade and now has a robust history of clinical use in approximately 10,000 patients.

The totality of evidence generated from the CONVERGE trial and published literature provides reasonable assurance of the safety and effectiveness of the Hybrid Convergent procedure for the treatment of longstanding-persistent AF, which AtriCure believes will facilitate evidence-based decision-making between physicians and patients in addressing this disease for which there are no treatment options.

A post-approval study synopsis is proposed herein to bolster the results of the CONVERGE pre-market pivotal study. Specifically, the aim of this study is to:

  1. Further confirm the effectiveness of the EPi-sense device in a larger sample size by narrowing confidence intervals.
  2. Demonstrate the proposed standard of care patient guidelines and mitigations for inflammatory pericardial effusions further reduce the observed safety event rates.
  3. Demonstrate that the CONVERGE pre-market pivotal study results are generalizable across operators with varying levels of experience.

Collect and report on long term outcomes of the Hybrid Convergent procedure.

03

Conditions studied

  • Chronic Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years and \< 80 years at time of enrollment consent;
  2. Left atrium ≤ 6.0 cm assessed with Transthoracic Echocardiography [TTE] with parasternal 4 chamber view or equivalent imaging modality;
  3. or intolerant to at least one AAD (class I and/or III);
  4. Subject has symptomatic (e.g. palpitations, shortness of breath, fatigue) longstanding persistent atrial fibrillation as defined by the 2017 HRS/EHRA/ECAS Guidelines (> 12 months of continuous AF);
  5. > 12 months; and
  6. Provides written .

Exclusion criteria

Exclusion Criteria:

  1. Patients requiring concomitant surgery such as valvular repair or replacement, coronary artery bypass graft (CABG) surgery and atrial septal defect closure;
  2. \< 35%;
  3. Pregnant or planning to become pregnant during study;
  4. Co-morbid medical conditions that limit one-year ;
  5. Previous cardiac surgery;
  6. History of pericarditis;
  7. Previous cerebrovascular accident (CVA), excluding fully resolved ;
  8. Patients who have active infection or sepsis
  9. Patients with esophageal ulcers strictures and varices;
  10. Patients with renal dysfunction who are not on dialysis (defined as ≤ 40);
  11. Patients who are for anticoagulants such as heparin and coumadin;
  12. Patients who are being treated for ventricular arrhythmias;
  13. Patients who have had more than 2 prior left atrial catheter ablations for AF. NOTE: Note: Prior ablations should be limited to failed Pulmonary Vein Isolation (PVI) and no other left atrial lesions;
  14. Current participation in another clinical investigation of a medical device or a drug, or recent participation in such a study within 30 days prior to study enrollment;
  15. Not competent to legally represent him or herself (e.g., requires a guardian or caretaker as a legal representative);
  16. Patient has presence of thrombus in the left atrium determined by intraoperative TEE;
  17. Patient exhibits pulmonary vein stenosis in one or more of the pulmonary veins >50 % stenosis;
  18. Planned Left Atrial Appendage Management (LAAM) with an endocardial implantable device during the course of the study;
  19. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
  20. Presence of Barretts esophagitis
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Other
    Hybrid Convergent

    Once the procedure intra-op exclusion conditions have been evaluated, the Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®- Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.

    Device: Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF

Interventions

  • DeviceEpicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF

    Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. This will be done endocardially using an irrigated endocardial ablation catheter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation. .

06

What researchers measure

Primary outcomes

  1. Freedom from AF/AFL/AT >30 seconds through 12 months absent new or increased dose of class I/III AAD.

    Primary Effectiveness Endpoint: The primary effectiveness endpoint is defined as the number of participants that exhibit freedom from AF/AT/AFL absent class I and III AADs except for a previously failed or intolerant class I or III AAD with no increase in dosage following the 90-day blanking period through the 12-months post procedure follow-up visit. The primary effectiveness endpoint will be evaluated based on the first 24 hours of the 7-days Holter monitoring. Participants will be considered failures if any of the following conditions are observed: AF/AFL/AT greater than 30 seconds, new or increased dose of previously failed AAD through 12 month post procedure visit, Cardioversion through 12 months post procedure, left sided catheter ablation through 12 months post procedure and catheter ablation for right sided typical atrial flutter. Failures will be compared to total cohort to establish a success rate.

    Time frame: 1 year

  2. Primary Safety Endpoint, Incidence of defined Major Adverse Events

    The primary safety endpoint for the study is defined as the number of participants that exhibit device or procedure-related major adverse events (MAEs) for subjects undergoing the Hybrid Convergent procedure from the index procedure through 30-days post procedure. Participants will be considered failures if the following is exhibted: * Pericardial effusions with cardiac tamponade defined as effusions resulting in hemodynamic compromise. * Severe pulmonary vein (PV) stenosis * Excessive bleeding requiring reoperation * Myocardial infarction (MI); * Stroke, transient ischemic attacks (TIA); * Atrioesophageal fistula (AEF) through 3-months post-procedure; * Phrenic nerve injury * Death Failures will be compared to total cohort of participants to establish success rate.

    Time frame: 30-days post procedure

Secondary outcomes

  1. Incidence of significant pericardial effusion

    • Number of participants that exhibit clinically significant pericardial effusions that require percutaneous or surgical treatment post-procedure. A significant pericardial effusion in one which results in hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in 1 cm or more pericardial effusion as documented by echocardiography. Failures will be compared to total cohort of participants to establish success rate.

    Time frame: 12 months

  2. Incidence of Serious Adverse Events (SAE) through 12 months

    • Device and procedure-related serious adverse events reported through 12 months post-procedure

    Time frame: 12 months

  3. Increase or decrease in AF symptoms from baseline

    • Change in AF symptoms from baseline to 12-, 18-, 24- and 36- months post-procedure based on Quality of Life (QoL) assessment using The Atrial Fibrillation Effect on Quality-of-life Questionnaire ( AFEQT)

    Time frame: 3 years

  4. Freedom from AF/AT/AFL >30 seconds with previously or intolerant failed class I/III AAD

    • Freedom from AF/AT/AFL \>30 seconds duration absent class I and III AADs except for a previously failed or intolerant class I or III AAD with no increase in dosage following the 90-day blanking period through the 12-months post procedure follow-up visit. Evaluated based on the first 24 hours of the 7-days Holter monitoring and symptom-driven event monitoring

    Time frame: 12 months

  5. Freedom from any AF/AFL/AT >30 seconds without a Class I/III

    • Freedom from any AF/AFL/AT \>30 seconds duration without a Class I/III AAD prescribed for AF following the 90-day blanking period through 12- 18-, 24- and 36- months post-procedure

    Time frame: 3 years

  6. Freedom from any AF/AFL/AT >30 seconds with or without a Class I/III AAD

    • Freedom from any AF/AFL/AT \>30 seconds duration with or without an AAD prescribed for AF following the 90-day blanking period through 12-, 18-, 24- and 36- months post -procedure

    Time frame: 3 years

  7. Number of participants with a reduction of AF burden

    • Residual AF burden / reduction in overall AF burden at 12-, 18-, 24- and 36-months post procedure when compared to baseline. No change or increase in burden will be considered a failure. Failures will be compared to total cohort of participants to establish success rate compared to baseline.

    Time frame: 3 years

  8. Number of Participants with an decrease in AFEQT Questionnaire Quality of Life (Qol) Score

    • Change in AF-specific Quality of Life (QoL) score(s) at 12-, 18-, 24- and 36- months post-index procedure when compared to baseline score. The increase in scores will be compared to baseline to determine comparative success or failure.

    Time frame: 3 years

  9. Number of participants with less than 30 seconds of AF/AFL/AT

    Freedom from AF/AFL/AT effectiveness secondary endpoints at 12-months will be evaluated from the 7-day rhythm recording and, also from the first 24 hours of a 7-days Holter. Freedom from AF/AFL/AT effectiveness secondary endpoints at 18-, 24- and 36- months will be evaluated from the 7-day rhythm recording. All burden effectiveness endpoints will be assessed from 7-days Holter for all subjects and separately for subjects with ILR/PPM data. Success or failure will be defined as AF/AFL/AT greater than 30 seconds duration. Failures will be compared to total cohort of participants to establish success rate.

    Time frame: 3 years

07

Study locations

13 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Feb 2027, 58 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 58 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Feb 2027, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
May 26, 2022
StartActual
Apr 13, 2022
Primary completionEst.
Feb 26, 2027was Jan 2027
CompletionEst.
Nov 21, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 1, 2027→Feb 26, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Jan 1, 2027→Feb 26, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05393180
Lead sponsor
AtriCure, Inc.
Responsible party
Sponsor
First posted
May 26, 2022
Start date
Apr 13, 2022
Primary completion
Feb 26, 2027 (estimated)
Completion
Nov 21, 2028 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion